TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints
TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.
- admin's blog
- Login or register to post comments
- Feed: news-medical.net-disease-news
- Original article
Yahoo! BOSS
No related items were found.
Yahoo! BOSS Images
No related items were found.
